Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
PURPOSE
The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990.
MATERIALS AND METHODS
Data on 9,728 men with metastatic nonseminomatous germ cell tumors treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Europe, North America, and Australia. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS). The survival estimates were updated for the current era. Additionally, a novel prognostic model for PFS was developed in 3,542 patients with complete information on potentially relevant variables. The results were validated in an independent data set.
RESULTS
Compared with the original IGCCCG publication, 5-year PFS remained similar in patients with good prognosis with 89% (87%-91%) versus 90% (95% CI, 89 to 91), but the 5-year OS increased from 92% (90%-94%) to 96% (95%-96%). In patients with intermediate prognosis, PFS remained similar with 75% (71%-79%) versus 78% (76%-80%) and the OS increased from 80% (76%-84%) to 89% (88%-91%). In patients with poor prognosis, the PFS increased from 41% (95% CI, 35 to 47) to 54% (95% CI, 52 to 56) and the OS from 48% (95% CI, 42 to 54) to 67% (95% CI, 65 to 69). A more granular prognostic model was developed and independently validated. This model identified a new cutoff of lactate dehydrogenase at a 2.5 upper limit of normal and increasing age and presence of lung metastases as additional adverse prognostic factors. An online calculator is provided ( https://www.eortc.org/IGCCCG-Update ).
CONCLUSION
The IGCCCG Update model improves individual prognostication in metastatic nonseminomatous germ cell tumors. Increasing age and lung metastases add granularity to the original IGCCCG classification as adverse prognostic factors.
Top-30
Journals
|
2
4
6
8
10
12
14
|
|
|
Frontiers in Oncology
14 publications, 7.45%
|
|
|
Clinical Genitourinary Cancer
10 publications, 5.32%
|
|
|
Cancers
6 publications, 3.19%
|
|
|
International Journal of Molecular Sciences
4 publications, 2.13%
|
|
|
European Urology Open Science
4 publications, 2.13%
|
|
|
Journal of Clinical Oncology
4 publications, 2.13%
|
|
|
Malignant tumours
4 publications, 2.13%
|
|
|
British Journal of Cancer
3 publications, 1.6%
|
|
|
Cancer
3 publications, 1.6%
|
|
|
Pediatric Blood and Cancer
3 publications, 1.6%
|
|
|
Cancer Medicine
3 publications, 1.6%
|
|
|
Medicina
3 publications, 1.6%
|
|
|
Urologic Oncology: Seminars and Original Investigations
3 publications, 1.6%
|
|
|
Cureus
3 publications, 1.6%
|
|
|
Journal of Clinical Medicine
3 publications, 1.6%
|
|
|
Biomedicines
2 publications, 1.06%
|
|
|
World Journal of Urology
2 publications, 1.06%
|
|
|
International Urology and Nephrology
2 publications, 1.06%
|
|
|
Human Pathology
2 publications, 1.06%
|
|
|
Urologic Clinics of North America
2 publications, 1.06%
|
|
|
International Journal of Clinical Oncology
2 publications, 1.06%
|
|
|
Andrology
2 publications, 1.06%
|
|
|
Tumor Diagnostik und Therapie
2 publications, 1.06%
|
|
|
Japanese Journal of Clinical Oncology
2 publications, 1.06%
|
|
|
Onkourologiya
2 publications, 1.06%
|
|
|
Urology Case Reports
2 publications, 1.06%
|
|
|
Mediastinum
2 publications, 1.06%
|
|
|
BMC Cancer
2 publications, 1.06%
|
|
|
European Journal of Cancer
2 publications, 1.06%
|
|
|
2
4
6
8
10
12
14
|
Publishers
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Elsevier
48 publications, 25.53%
|
|
|
Springer Nature
29 publications, 15.43%
|
|
|
MDPI
21 publications, 11.17%
|
|
|
Frontiers Media S.A.
18 publications, 9.57%
|
|
|
Wiley
18 publications, 9.57%
|
|
|
American Society of Clinical Oncology (ASCO)
6 publications, 3.19%
|
|
|
AME Publishing Company
6 publications, 3.19%
|
|
|
Georg Thieme Verlag KG
5 publications, 2.66%
|
|
|
SAGE
4 publications, 2.13%
|
|
|
Russian Society of Clinical Oncology
4 publications, 2.13%
|
|
|
S. Karger AG
4 publications, 2.13%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 1.6%
|
|
|
Taylor & Francis
3 publications, 1.6%
|
|
|
Oxford University Press
2 publications, 1.06%
|
|
|
BMJ
2 publications, 1.06%
|
|
|
Publishing House ABV Press
2 publications, 1.06%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 1.06%
|
|
|
Spandidos Publications
1 publication, 0.53%
|
|
|
CMA Impact Inc.
1 publication, 0.53%
|
|
|
Society for Translational Oncology
1 publication, 0.53%
|
|
|
Hellenic Society of Medical Oncology (He.S.M.O.)
1 publication, 0.53%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 0.53%
|
|
|
Medknow
1 publication, 0.53%
|
|
|
American Medical Association (AMA)
1 publication, 0.53%
|
|
|
Eco-Vector LLC
1 publication, 0.53%
|
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.